Vaccine · Immune activation · developed by Mannkind
Synchrotope TA2M is a cancer vaccine given with immunotherapy, studied in melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00023647 | Phase 1 | Melanoma (Skin) | Completed | MNKD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Melanoma (Skin)
Updated Oct 18, 2026. Something wrong or missing? Report it on the MNKD page.
See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MNKD catalysts and pipeline →